CD274 and liver disorder: Sindhu et al. (2017) report a patient with metastatic angiosarcoma expressing PD-L1, treated with off-label pembrolizumab 2 mg/kg every 21 d for 13 cycles with shrinkage of his liver disease and no new facial lesions during an 8-mo follow-up period off treatment.